Volume 22 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(1): 39-41
YU Liang, ZHAO Hao, YUAN Xiaoying, SONG Ying, LI Jiajia. Establishment of CD22 reference intervals in peripheral blood by flow cytometry[J]. Chinese Journal of General Practice, 2024, 22(1): 39-41. doi: 10.16766/j.cnki.issn.1674-4152.003326
Citation: YU Liang, ZHAO Hao, YUAN Xiaoying, SONG Ying, LI Jiajia. Establishment of CD22 reference intervals in peripheral blood by flow cytometry[J]. Chinese Journal of General Practice, 2024, 22(1): 39-41. doi: 10.16766/j.cnki.issn.1674-4152.003326
shu

Establishment of CD22 reference intervals in peripheral blood by flow cytometry

doi: 10.16766/j.cnki.issn.1674-4152.003326
  • 1.

    Central Laboratory, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0358

  • Received Date: 2023-05-30
    Available Online: 2024-03-09
    Abstract
  •   Objective  To detect the percentage of CD22 in peripheral blood lymphocytes of healthy adults by flow cytometry. The reference range for healthy adults was established according to the requirements of Clinical and Laboratory Standards Institute EP28-A3c.  Methods  Peripheral blood was collected from healthy people who underwent physical examination in Peking University People' s Hospital and the First Affiliated Hospital of Bengbu Medical University from July to November 2022. The peripheral blood CD22 levels of 130 healthy adults were measured by flow cytometry, and the data of each group were grouped according to region, sex and age according to the grouping requirements in the EP28-A3c file, so as to establish the corresponding biological reference interval.  Results  The level of CD22 in peripheral blood of healthy adults was normally distributed, and the positive rates of CD22 in peripheral blood of healthy adults in Beijing and Anhui were (10.87±4.37)% and (12.62±4.03)%, respectively, with no statistical significance (t=1.336, P=0.205). The positive rates of CD22 in male and female peripheral blood were (11.76±4.86)% and (11.85±3.69)%, respectively, and the difference was not statistically significant (t=0.111, P=0.911). They were divided into ≤35 years old group, 36-60 years old group and > 60 years old group. The positive rate of CD22 in peripheral blood of the three groups were (11.53±3.20)%, (11.61±3.80)% and (12.73±6.36)%, respectively, and there was no statistical significance (F=0.761, P=0.469). According to the 90% confidence interval recommended by the International Committee for Clinical Laboratory Standards, the reference intervals of CD22 in lymphocytes (flow cytometry) was 4.82%-18.80%.  Conclusion  The reference intervals of CD22 positive rate in peripheral blood of healthy adults are consistent in different regions, gender and age. It can be combined to establish the reference intervals of CD22 positive rate in peripheral blood of healthy adults.

     

    • FullText(HTML)
  • loading
    • References(19)
  • [1]
    武晓静, 邵宗鸿. CD22表达、功能及调控的研究进展[J]. 中国实验血液学杂志, 2015, 23(2): 573-577. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201502058.htm

    WU X J, SHAO Z H. Recent advances of researches on expression, function and regulation of CD22 review[J]. Journal of Experimental Hematology, 2015, 23(2): 573-577. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201502058.htm
    [2]
    Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline-third edition. NCCLS Document EP28-A3c[M]. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
    [3]
    AKATSU C, SHEIKH A A, MATSUBARA N, et al. The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45-/- immunodeficient B cells[J]. Sci Signal, 2022, 15(723): eabf9570. DOI: 10.1126/scisignal.abf9570.
    [4]
    李薇, 曾伟杰, 彭浩, 等. CD19和CD22双靶点CAR-T细胞对肿瘤细胞的杀伤作用[J]. 中国肿瘤生物治疗杂志, 2022, 29(7): 623-630. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202207003.htm

    LI W, ZENG W J, PENG H, et al. The killing effect of CD19 and CD22 dual target CAR T cells on tumor cells[J]. Chinese Journal of Tumor Biotherapy, 2022, 29(7): 623-630. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202207003.htm
    [5]
    徐童, 刘辉. 嵌合抗原受体T细胞治疗血液肿瘤的研究进展[J]. 中华微生物学和免疫学杂志, 2021, 41(7): 560-564. doi: 10.3760/cma.j.cn112309-20210520-00167

    XU T, LIU H. Research progress of chimeric antigen receptor T cells therapy in hematological malignancies[J]. Chinese Journal of Microbiology and Immunology, 2021, 41(7): 560-564. doi: 10.3760/cma.j.cn112309-20210520-00167
    [6]
    BODET-MILIN C, FERRER L, PALLARDY A, et al. Preclinical basis for lymphoma treatment with the CD22-targeting antibody-drug conjugate pinatuzumab vedotin[J]. BJH, 2020, 188(3): 460-477. doi: 10.1111/bjh.16179
    [7]
    FRY T J, SHAH N N, ORENTAS R J, et al. CD22-targeted CAR-T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy[J]. Nat Med, 2018, 24(1): 20-28. doi: 10.1038/nm.4441
    [8]
    穆娟, 吕海容, 李静怡, 等. CD22 CAR-T挽救治疗CD19 CAR-T治疗后短期复发的TP53突变阳性难治急性B淋巴细胞白血病一例[J]. 天津医药, 2020, 48(4): 308-312. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202004016.htm

    MU J, LYU H R, LI J Y, et al. CD22 CAR-T salvage therapy for a refractory acute B lymphocytic leukemia patient with TP53 positive mutation and short-term recurrence after remission from CD19 CAR-T therapy[J]. Tianjin Medical Journal, 2020, 48(4): 308-312. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202004016.htm
    [9]
    丁雅雯, 王芃堉, 焦文静, 等. 弥漫大B细胞淋巴瘤骨髓侵犯形态学及免疫表型特点分析[J]. 天津医药, 2020, 48(3): 204-208. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202003011.htm

    DING Y W, WANG P Y, JIAO W J, et al. Analysis of morphological and immunophenotypic features of bone marrow invasion in diffuse large B-cell lymphoma[J]. Tianjin Medical Journal, 2020, 48(3): 204-208. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202003011.htm
    [10]
    王雯娟, 赵娟, 贺鹏程, 等. 淋巴瘤细胞白血病骨髓细胞形态学和免疫分型的特点及其在诊断中的价值[J]. 中国实验血液学杂志, 2018, 26(2): 459-463. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201802030.htm

    WANG W J, ZHAO J, HE P C, et al. Characteristics and Diagnostic Values of Bone Marrow Cell Mor-phology and Immunophenotyping in Lymphoma Cell Leukemia[J]. Journal of Experimental Hematology, 2018, 26(2): 459-463. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201802030.htm
    [11]
    周月平. 骨髓形态联合免疫分型检测在慢性淋巴细胞白血病中的应用[J]. 中国当代医药, 2020, 27(24): 158-160. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD202024043.htm

    ZHOU Y P. Application of marrow morphology combined immunotyping in chronic lymphoblastic leukemia[J]. China Modern Medicine, 2020, 27(24): 158-160. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD202024043.htm
    [12]
    赵雪飞, 王洪岩, 赵旭, 等. 急性淋巴细胞白血病的免疫分型和基因的研究[J]. 中国实验血液学杂志, 2018, 26(4): 947-952. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201804004.htm

    ZHAO X F, WANG H Y, ZHAO X, et al. Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia[J]. Journal of Experimental Hematology, 2018, 26(4): 947-952. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201804004.htm
    [13]
    裴东旭, 张鹏, 段晓克, 等. CLLflow和Moreau评分系统对慢性淋巴细胞白血病诊断效能比较[J]. 中华检验医学杂志, 2023, 46(1): 81-86.

    PEI D X, ZHANG P, DUAN X K, et al. Diagnostic efficacy comparison between CLLflow score and Moreau score for chronic lymphocytic leukemia[J]. Chinese Journal of Laboratory Medicine, 2023, 46(1): 81-86.
    [14]
    KANTARJIAN H M, DAANGELO D J, STELLJES M, et al. Inotuzumabozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study[J]. Cancer, 2019, 125(14): 2474-2487. doi: 10.1002/cncr.32116
    [15]
    徐力, 聂柳燕, 汪胡燕, 等. 自身免疫性疾病中程序性细胞死亡因子1及其配体的研究进展[J]. 中华全科医学, 2022, 20(5): 832-835, 843. doi: 10.16766/j.cnki.issn.1674-4152.002466

    XU L, NIE L Y, WANG H Y, et al. Research progress of programmed cell death-1 and its ligand in autoimmune diseases[J]. Chinese Journal of General Practice, 2022, 20(5): 832-835, 843. doi: 10.16766/j.cnki.issn.1674-4152.002466
    [16]
    王欣, 张庆, 罗帅寒天, 等. 系统性红斑狼疮治疗靶点相关研究进展[J]. 中南大学学报(医学版), 2021, 46(11): 1267-1275. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202111013.htm

    WANG X, ZHANG Q, LUO S H T, et al. Advances in therapeutic targets-related study on systemic lupus erythematosus[J]. Journal of Central South University, 2021, 46(11): 1267-1275. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202111013.htm
    [17]
    王晓霞, 王洪, 何佳莉, 等. 我国风湿性疾病药物临床试验现状分析[J]. 中华风湿病学杂志, 2020, 24(4): 240-246.

    WANG X X, WANG H, HE J L, et al. Analysis of drug clinical trials for rheumatic diseases in China[J]. Chinese Journal of Rheumatology, 2020, 24(4): 240-246.
    [18]
    BRANDL C, ANGERMULLER S, NITSCHKE L, et al. Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy[J]. Eur J Immunol, 2020, 50(11): 1834-1837.
    [19]
    BEDNAR K J, NYCHOLAT C M, RAO T S, et al. Exploiting CD22 to selectively tolerize autoantibody producing B-cells in rheumatoid arthritis[J]. ACS Chem Biol, 2019, 14(4): 644-654.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (176) PDF downloads(22) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return